Alprazolam
| Evidence Level: L3 | Predicted Indications: 2 |
Table of Contents
Alprazolam: Insomnia (disease)
One-Sentence Summary
Alprazolam is a benzodiazepine with sedative and anxiolytic effects. The TxGNN model predicts it may be effective for insomnia (disease), but no clinical trials are registered and the supporting literature is mostly indirect, with one retrospective observational study that includes alprazolam in patients with insomnia. The evidence level is L3.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Insomnia (disease) |
| TxGNN Prediction Score | 0.9981 |
| Evidence Level | L3 |
| Canada Market Status | Marketed (marketed DINs: 13 of 13) |
| Number of DINs | 13 (marketed: 13) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on class-level pharmacology, alprazolam is a benzodiazepine that enhances GABA-A receptor activity, which produces sedative and anxiolytic effects.
Insomnia often co-occurs with anxiety, so a plausible link exists: a drug that calms anxiety and promotes sedation could also help sleep. However, this link rests on class pharmacology rather than direct evidence. Benzodiazepines carry risks of dependence, tolerance, falls and cognitive impairment, especially in older adults, and these weigh against repurposing.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The most relevant publication is a retrospective observational study. No randomized trial of alprazolam for insomnia was found. Most other records are general reviews, utilization studies or studies of other drugs.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39183410 | 2024 | Retrospective observational study | Medicine | 116 patients with coronary heart disease and insomnia; alprazolam was the control treatment, compared with Du Meridian moxibustion plus ear acupuncture, assessing symptoms and neurotransmitter levels |
| 36692463 | 2023 | Meta-analysis / observational | Acta Pharmaceutica | Tranquilizer use in elderly patients with chronic diseases, assessing doses and adverse effects (indirect) |
| 23330992 | 2013 | Review | Expert Opin Drug Metab Toxicol | Pharmacokinetics of anxiolytic drugs (indirect) |
| 37984023 | 2024 | Predictive modelling | Value Health Reg Issues | Trends and economic burden of benzodiazepine use, including for insomnia (indirect) |
| 15341891 | 2004 | Prescription pattern study | Sleep Medicine | Hypnotic prescribing patterns in a managed-care population (indirect) |
| 38363887 | 2024 | Cross-sectional study | Medicine | Insomnia among COVID-19 survivors; not specific to alprazolam (indirect) |
Canada Market Information
| DIN | Product Name |
|---|---|
| 02243612 | APO-ALPRAZ TS |
| 00548359 | XANAX |
| 00865397 | APO-ALPRAZ |
| 01913492 | TEVA-ALPRAZOLAM |
| 01908189 | PRO-ALPRAZOLAM |
All 13 single-ingredient licences are valid; the table lists the first five.
Safety Considerations
- Drug Interactions: 100 interactions were recorded. Major interactions include morphine and liposomal morphine. Moderate interactions include aprepitant, bupropion, cimetidine, clarithromycin, clotrimazole, dronabinol, eliglustat, glycerol phenylbutyrate, metoclopramide and miconazole. Antacids such as aluminum hydroxide, calcium carbonate and magnesium salts, and corticosteroids such as betamethasone and dexamethasone, are minor.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score is high (0.9981), but the only study involving alprazolam in insomnia is a retrospective observational study, with no randomized trial and no registered clinical trials. Dependence, tolerance, falls and cognitive risks of benzodiazepines weigh against repurposing for a chronic sleep condition.
To proceed, the following is needed:
- Controlled trials of alprazolam specifically for insomnia
- Detailed mechanism of action data
- Package insert warnings and contraindications from Health Canada
- A risk assessment for dependence and falls, particularly in older adults
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.